Abstract
Background: Presence of dementia is a contraindication for DBS treatment of Parkinson's disease. Recent evidence suggests that borderline cognitive function, as measured with a common screening measure, the Mattis Dementia Rating Scale, has a negative impact on quality of life (QoL) after DBS of the STN. Methods: We attempted to replicate and extend this finding in a larger group of patients with a wider range of preoperative global cognitive performance. Results: Our data indicate that performance on the screening measure is not associated with QoL or medical outcomes, even with scores well below the cutoff for identifying dementia. Conclusions: This cognitive screening measure lacks sufficient sensitivity to warrant its use in predicting which patients will show QoL benefit from DBS.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1279-1283 |
| Number of pages | 5 |
| Journal | Movement Disorders |
| Volume | 30 |
| Issue number | 9 |
| DOIs | |
| State | Published - Aug 1 2015 |
Bibliographical note
Funding Information:D.F. has received grant funding from the National Institutes of Health (NIH; R01 NS058706‐01 and R01 NS073717‐01). R.M.B. has received grant funding from the Epilepsy Foundation (246507) and the NIH (R01 NS035929‐01; KL2TR000440). A.G.M. has served as a consultant with Spinal Modulation and Functional Neuromodulation; has received grant funding from the Department of Defense (DOD006469) and the NIH (R01 HD061363‐01); and holds distribution rights with Enspire, ATI, and Cardionomics.
Funding Information:
Portions of this research were funded by the Cleveland Clinic Center for Neurological Restoration and the National Institutes of Health (R01 NS058706‐01 [to D.F.], KL2TR000440 [to R.M.B.], and R01 HD061363‐01 [to A.G.M.]). Funding agencies:
Publisher Copyright:
© 2015 International Parkinson and Movement Disorder Society
Keywords
- Parkinson's disease
- cognition
- deep brain stimulation
- outcome research
- quality of life